PriceTargets.com logo

BioMarin Pharmaceutical - BMRN Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $88.61
  • Forecasted Upside: 64.64%
  • Number of Analysts: 25
  • Breakdown:
  • 1 Sell Ratings
  • 8 Hold Ratings
  • 16 Buy Ratings
  • 0 Strong Buy Ratings
$53.82 As of 12/4/2025 05:00 PM ET
▼ -0.49 (-0.90%)

This chart shows the closing price for BMRN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New BioMarin Pharmaceutical Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BMRN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BMRN

Analyst Price Target is $88.61
▲ +64.64% Upside Potential
This price target is based on 25 analysts offering 12 month price targets for BioMarin Pharmaceutical in the last 3 months. The average price target is $88.61, with a high forecast of $126.00 and a low forecast of $55.00. The average price target represents a 64.64% upside from the last price of $53.82.

This chart shows the closing price for BMRN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 25 investment analysts is to moderate buy stock in BioMarin Pharmaceutical. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 12 buy ratings
  • 9 hold ratings
  • 0 sell ratings
Ratings as of
6/12/2024
  • 1 strong buy ratings
  • 14 buy ratings
  • 8 hold ratings
  • 0 sell ratings
Ratings as of
9/10/2024
  • 1 strong buy ratings
  • 15 buy ratings
  • 7 hold ratings
  • 0 sell ratings
Ratings as of
12/9/2024
  • 0 strong buy ratings
  • 17 buy ratings
  • 7 hold ratings
  • 0 sell ratings
Ratings as of
3/9/2025
  • 0 strong buy ratings
  • 17 buy ratings
  • 6 hold ratings
  • 0 sell ratings
Ratings as of
6/7/2025
  • 0 strong buy ratings
  • 18 buy ratings
  • 7 hold ratings
  • 0 sell ratings
Ratings as of
9/5/2025
  • 0 strong buy ratings
  • 17 buy ratings
  • 5 hold ratings
  • 1 sell ratings
Ratings as of
11/4/2025
  • 0 strong buy ratings
  • 16 buy ratings
  • 8 hold ratings
  • 1 sell ratings
Ratings as of
12/4/2025

Latest Recommendations

  • 0 strong buy ratings
  • 16 buy ratings
  • 8 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
12/3/2025Leerink PartnrsDowngradeStrong-Buy ➝ Hold
12/3/2025Leerink PartnersDowngradeOutperform ➝ Market Perform$82.00 ➝ $60.00
12/1/2025Weiss RatingsReiterated RatingSell (D) ➝ Sell (D)
11/24/2025Weiss RatingsReiterated RatingSell (D) ➝ Sell (D)
11/6/2025Stifel NicolausReiterated RatingBuy ➝ Hold$73.00 ➝ $61.00
11/3/2025Tudor PickeringSet Target$88.00
11/3/2025Sanford C. BernsteinLower TargetOutperform ➝ Outperform$95.00 ➝ $88.00
10/28/2025Royal Bank Of CanadaReiterated RatingSector Perform ➝ Sector Perform$66.00
10/28/2025Truist FinancialLower TargetBuy ➝ Buy$90.00 ➝ $80.00
10/28/2025Wolfe ResearchReiterated RatingOutperform ➝ Outperform
10/28/2025WedbushReiterated RatingOutperform$94.00
10/28/2025Wells Fargo & CompanyLower TargetOverweight ➝ Overweight$90.00 ➝ $70.00
10/28/2025Stifel NicolausLower TargetBuy ➝ Buy$91.00 ➝ $73.00
10/28/2025BarclaysLower TargetOverweight ➝ Overweight$86.00 ➝ $80.00
10/28/2025Morgan StanleyLower TargetOverweight ➝ Overweight$104.00 ➝ $98.00
10/27/2025HC WainwrightLower TargetNeutral ➝ Neutral$60.00 ➝ $55.00
10/9/2025JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$116.00 ➝ $119.00
10/8/2025Weiss RatingsReiterated RatingSell (D+) ➝ Sell (D+)
9/27/2025Weiss RatingsReiterated RatingSell (D+) ➝ Sell (D+)
9/8/2025HC WainwrightInitiated CoverageNeutral$60.00
9/3/2025Raymond James FinancialInitiated CoverageOutperform$85.00
8/13/2025Zacks ResearchDowngradeStrong-Buy ➝ Hold
8/6/2025GuggenheimBoost TargetBuy ➝ Buy$101.00 ➝ $106.00
8/5/2025WedbushReiterated RatingOutperform$94.00
8/5/2025UBS GroupBoost TargetBuy ➝ Buy$113.00 ➝ $114.00
7/22/2025Morgan StanleyLower TargetOverweight ➝ Overweight$97.00 ➝ $96.00
7/15/2025Wolfe ResearchSet TargetOutperform ➝ Outperform$95.00
7/14/2025JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$108.00 ➝ $113.00
7/3/2025Morgan StanleyInitiated CoverageOverweight$97.00
5/5/2025The Goldman Sachs GroupLower TargetBuy ➝ Buy$124.00 ➝ $104.00
5/2/2025CitigroupLower TargetNeutral ➝ Neutral$82.00 ➝ $78.00
2/24/2025OppenheimerUpgradeMarket Perform ➝ Outperform$98.00
2/20/2025WedbushReiterated RatingOutperform$94.00
2/20/2025CitigroupBoost TargetNeutral ➝ Neutral$81.00 ➝ $82.00
2/20/2025ScotiabankBoost TargetSector Perform ➝ Sector Perform$78.00 ➝ $80.00
2/20/2025Royal Bank Of CanadaReiterated RatingSector Perform ➝ Sector Perform$70.00 ➝ $70.00
2/20/2025Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$90.00 ➝ $90.00
2/20/2025UBS GroupBoost TargetBuy ➝ Buy$109.00 ➝ $113.00
2/20/2025Piper SandlerBoost TargetOverweight ➝ Overweight$122.00 ➝ $126.00
2/20/2025Bank of AmericaBoost TargetBuy ➝ Buy$99.00 ➝ $103.00
12/12/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$90.00 ➝ $90.00
11/15/2024Wolfe ResearchInitiated CoverageOutperform$95.00
11/4/2024WedbushUpgradeStrong-Buy
10/30/2024CitigroupLower TargetNeutral ➝ Neutral$93.00 ➝ $81.00
10/30/2024Cantor FitzgeraldLower TargetOverweight ➝ Overweight$110.00 ➝ $90.00
10/30/2024Canaccord Genuity GroupLower TargetHold ➝ Hold$93.00 ➝ $84.00
10/30/2024JPMorgan Chase & Co.Lower TargetOverweight ➝ Overweight$110.00 ➝ $109.00
10/30/2024Evercore ISILower TargetOutperform ➝ Outperform$115.00 ➝ $105.00
10/30/2024Royal Bank Of CanadaReiterated RatingSector Perform ➝ Sector Perform$80.00 ➝ $80.00
10/30/2024UBS GroupBoost TargetBuy ➝ Buy$104.00 ➝ $106.00
10/30/2024Robert W. BairdLower TargetNeutral ➝ Neutral$72.00 ➝ $65.00
10/30/2024William BlairDowngradeOutperform ➝ Market Perform
10/10/2024Raymond James FinancialReiterated RatingOutperform$79.00
10/4/2024Royal Bank Of CanadaLower TargetSector Perform ➝ Sector Perform$85.00 ➝ $80.00
10/4/2024BarclaysLower TargetOverweight ➝ Overweight$110.00 ➝ $86.00
9/17/2024ScotiabankLower TargetSector Perform ➝ Sector Perform$95.00 ➝ $78.00
9/17/2024Wells Fargo & CompanyLower TargetOverweight ➝ Overweight$115.00 ➝ $90.00
9/17/2024Truist FinancialLower TargetBuy ➝ Buy$118.00 ➝ $90.00
9/17/2024Royal Bank Of CanadaLower TargetSector Perform ➝ Sector Perform$100.00 ➝ $85.00
9/17/2024Stifel NicolausLower TargetBuy ➝ Buy$115.00 ➝ $87.00
9/17/2024Bank of AmericaLower TargetBuy ➝ Buy$130.00 ➝ $115.00
9/17/2024Sanford C. BernsteinLower TargetOutperform ➝ Outperform$116.00 ➝ $90.00
9/13/2024Canaccord Genuity GroupReiterated RatingHold ➝ Hold$93.00 ➝ $93.00
9/9/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$110.00 ➝ $110.00
9/5/2024Royal Bank Of CanadaReiterated RatingSector Perform ➝ Sector Perform$100.00 ➝ $100.00
9/5/2024JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$111.00 ➝ $120.00
9/5/2024ScotiabankBoost TargetSector Perform ➝ Sector Perform$86.00 ➝ $95.00
9/5/2024Piper SandlerBoost TargetOverweight ➝ Overweight$107.00 ➝ $122.00
9/5/2024Truist FinancialLower TargetBuy ➝ Buy$140.00 ➝ $118.00
8/30/2024William BlairUpgradeStrong-Buy
8/27/2024Piper SandlerReiterated RatingOverweight ➝ Overweight$107.00 ➝ $107.00
8/21/2024Stifel NicolausBoost TargetBuy ➝ Buy$112.00 ➝ $115.00
8/20/2024Sanford C. BernsteinUpgradeMarket Perform ➝ Outperform$94.00 ➝ $110.00
8/6/2024TD CowenLower TargetBuy ➝ Buy$125.00 ➝ $120.00
8/6/2024ScotiabankBoost TargetSector Perform ➝ Sector Perform$85.00 ➝ $86.00
8/6/2024BarclaysLower TargetOverweight ➝ Overweight$111.00 ➝ $110.00
8/6/2024Royal Bank Of CanadaReiterated RatingSector Perform ➝ Sector Perform$100.00 ➝ $100.00
8/6/2024Stifel NicolausBoost TargetBuy ➝ Buy$108.00 ➝ $112.00
8/6/2024Evercore ISIBoost TargetOutperform ➝ Outperform$113.00 ➝ $115.00
8/5/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$110.00 ➝ $110.00
7/25/2024Canaccord Genuity GroupReiterated RatingHold ➝ Hold$89.00 ➝ $89.00
7/22/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$110.00 ➝ $110.00
6/27/2024Wells Fargo & CompanyBoost TargetOverweight ➝ Overweight$110.00 ➝ $115.00
5/17/2024Baird R WDowngradeStrong-Buy ➝ Hold
5/17/2024Robert W. BairdDowngradeOutperform ➝ Neutral$104.00 ➝ $72.00
5/14/2024Evercore ISIInitiated CoverageOutperform$113.00
4/26/2024Morgan StanleyLower TargetOverweight ➝ Overweight$115.00 ➝ $112.00
4/26/2024Canaccord Genuity GroupLower TargetHold ➝ Hold$91.00 ➝ $89.00
4/25/2024CitigroupLower TargetNeutral ➝ Neutral$94.00 ➝ $91.00
4/25/2024ScotiabankBoost TargetSector Perform ➝ Sector Perform$83.00 ➝ $85.00
4/25/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$110.00
4/25/2024Wells Fargo & CompanyBoost TargetOverweight ➝ Overweight$100.00 ➝ $110.00
2/29/2024Canaccord Genuity GroupReiterated RatingHold ➝ Hold$91.00
2/23/2024Piper SandlerLower TargetOverweight ➝ Overweight$115.00 ➝ $107.00
2/23/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$100.00
2/23/2024Royal Bank Of CanadaReiterated RatingSector Perform ➝ Sector Perform$100.00
1/30/2024Robert W. BairdLower TargetOutperform ➝ Outperform$127.00 ➝ $104.00
12/21/2023Stifel NicolausReiterated RatingBuy ➝ Buy$101.00
11/15/2023Wells Fargo & CompanyInitiated CoverageOverweight$100.00
11/7/2023Royal Bank Of CanadaReiterated RatingSector Perform ➝ Sector Perform$100.00
11/3/2023BMO Capital MarketsLower TargetOutperform ➝ Outperform$102.00 ➝ $100.00
11/2/2023Cantor FitzgeraldLower TargetOverweight ➝ Overweight$120.00 ➝ $100.00
11/2/2023BarclaysLower TargetOverweight ➝ Overweight$125.00 ➝ $111.00
11/2/2023Morgan StanleyLower TargetOverweight ➝ Overweight$125.00 ➝ $117.00
11/2/2023Piper SandlerLower TargetOverweight ➝ Overweight$125.00 ➝ $115.00
11/2/2023WedbushReiterated RatingNeutral$78.00
10/23/2023Sanford C. BernsteinUpgradeUnderperform ➝ Market Perform$82.00
10/16/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$120.00
9/28/2023Raymond James FinancialInitiated CoverageMarket Perform
9/25/2023Truist FinancialReiterated RatingBuy ➝ Buy$140.00
9/18/2023UBS GroupInitiated CoverageBuy$120.00
9/15/2023Truist FinancialReiterated RatingBuy ➝ Buy$140.00
9/14/2023WedbushReiterated RatingNeutral$71.00 ➝ $78.00
9/13/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$120.00
9/13/2023Royal Bank Of CanadaReiterated RatingSector Perform ➝ Sector Perform$100.00
9/13/2023GuggenheimReiterated RatingBuy ➝ Buy$110.00
8/1/2023Morgan StanleyLower TargetOverweight ➝ Overweight$129.00 ➝ $125.00
8/1/2023Royal Bank Of CanadaReiterated RatingSector Perform ➝ Sector Perform$100.00
8/1/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$120.00
8/1/2023WedbushLower TargetNeutral ➝ Neutral$73.00 ➝ $70.00
8/1/2023Stifel NicolausLower TargetBuy ➝ Buy$118.00 ➝ $108.00
7/27/2023ScotiabankInitiated CoverageSector Perform$95.00
7/21/2023Bank of AmericaLower TargetBuy$185.00
7/5/2023BMO Capital MarketsUpgradeMarket Perform ➝ Outperform$102.00
7/3/2023GuggenheimLower Target$120.00 ➝ $110.00
6/30/2023Truist FinancialBoost TargetBuy$125.00 ➝ $140.00
6/30/2023Robert W. BairdReiterated RatingOutperform ➝ Outperform$127.00
6/30/2023CitigroupLower TargetNeutral$103.00 ➝ $96.00
6/30/2023500.comReiterated RatingReiterates
6/30/2023WedbushBoost TargetNeutral$69.00 ➝ $73.00
4/27/2023888Reiterated RatingMaintains
4/27/2023GuggenheimLower Target$125.00 ➝ $120.00
4/27/2023Robert W. BairdBoost Target$112.00 ➝ $127.00
3/21/2023Sanford C. BernsteinInitiated CoverageUnderperform$81.00
3/7/2023BMO Capital MarketsLower TargetMarket Perform$107.00 ➝ $102.00
2/28/2023GuggenheimReiterated RatingBuy$125.00
2/28/2023Stifel NicolausBoost TargetBuy$114.00 ➝ $118.00
2/28/2023Canaccord Genuity GroupLower TargetHold$119.00 ➝ $112.00
2/28/2023WedbushLower TargetNeutral$83.00 ➝ $74.00
2/28/2023Morgan StanleyLower TargetOverweight$132.00 ➝ $131.00
2/28/2023Credit Suisse GroupBoost TargetOutperform$110.00 ➝ $127.00
2/22/2023Avian SecuritiesDowngradeMarket Perform
2/22/2023OppenheimerDowngradeOutperform ➝ Market Perform
2/21/2023CitigroupInitiated CoverageNeutral$116.00
2/3/2023Leerink PartnersBoost TargetOutperform$122.00 ➝ $130.00
1/30/2023BMO Capital MarketsInitiated CoverageMarket Perform$107.00
1/24/2023Morgan StanleyBoost TargetOverweight$113.00 ➝ $132.00
1/18/2023Canaccord Genuity GroupInitiated CoverageHold$119.00
1/11/2023WedbushBoost TargetNeutral$74.00 ➝ $83.00
1/9/2023GuggenheimBoost Target$120.00 ➝ $125.00
1/4/2023Bank of AmericaBoost Target$200.00
12/2/2022Evercore ISIBoost Target$130.00
11/29/2022Jefferies Financial GroupBoost TargetBuy$100.00 ➝ $120.00
10/31/2022OppenheimerUpgradeMarket Perform ➝ Outperform$92.00 ➝ $110.00
10/27/2022Credit Suisse GroupLower TargetOutperform$111.00 ➝ $110.00
10/27/2022Morgan StanleyBoost TargetOverweight$111.00 ➝ $113.00
10/24/2022JPMorgan Chase & Co.Lower TargetOverweight$140.00 ➝ $112.00
10/13/2022Morgan StanleyLower TargetOverweight$117.00 ➝ $111.00
10/13/2022Royal Bank Of CanadaBoost TargetSector Perform$90.00 ➝ $95.00
10/12/2022Cantor FitzgeraldBoost Target$110.00 ➝ $115.00
9/28/2022Stifel NicolausBoost Target$104.00
9/13/2022WedbushReiterated RatingNeutral$74.00
8/26/2022Robert W. BairdReiterated RatingOutperform ➝ Outperform$112.00
8/9/2022Credit Suisse GroupBoost Target$111.00
8/9/2022Piper SandlerBoost TargetOverweight$125.00 ➝ $128.00
8/4/2022Morgan StanleyBoost TargetOverweight$113.00 ➝ $117.00
8/4/2022Leerink PartnersBoost TargetOutperform$115.00 ➝ $122.00
8/4/2022BarclaysBoost TargetOverweight$112.00 ➝ $125.00
7/12/2022Cantor FitzgeraldInitiated CoverageOverweight$110.00
6/28/2022Robert W. BairdReiterated RatingOutperform ➝ Outperform$112.00
6/24/2022WedbushReiterated RatingHold$70.00
6/13/2022WedbushLower TargetOutperform ➝ Neutral$146.00 ➝ $70.00
6/6/2022Credit Suisse GroupBoost TargetOutperform$105.00 ➝ $106.00
5/4/2022Jefferies Financial GroupReiterated RatingBuy ➝ Buy$100.00
5/3/2022Stifel NicolausReiterated RatingBuy$96.00
4/28/2022WedbushLower Target$155.00 ➝ $147.00
4/25/2022Morgan StanleyUpgradeEqual Weight ➝ Overweight$96.00 ➝ $113.00
4/12/2022Morgan StanleyBoost TargetEqual Weight$90.00 ➝ $96.00
2/24/2022WedbushReiterated RatingOutperform$155.00
2/24/2022Piper SandlerBoost TargetOverweight$121.00 ➝ $125.00
2/18/2022Morgan StanleyReiterated RatingHold$90.00
1/10/2022Truist FinancialBoost Target$125.00 ➝ $135.00
12/2/2021Leerink PartnersReiterated RatingBuy
11/23/2021Robert W. BairdBoost TargetOutperform$101.00 ➝ $112.00
11/22/2021OppenheimerBoost TargetMarket Perform$84.00 ➝ $95.00
11/22/2021GuggenheimBoost TargetBuy$103.00 ➝ $120.00
11/22/2021Credit Suisse GroupBoost TargetOutperform$100.00 ➝ $105.00
11/22/2021JPMorgan Chase & Co.Boost TargetOverweight$129.00 ➝ $135.00
11/22/2021Morgan StanleyBoost TargetEqual Weight$82.00 ➝ $90.00
11/22/2021Leerink PartnersBoost TargetOutperform$112.00 ➝ $115.00
11/22/2021William BlairUpgradeMarket Perform ➝ Outperform
11/15/2021Leerink PartnersBoost TargetOutperform$108.00 ➝ $112.00
10/28/2021WedbushReiterated RatingOutperform$152.00
10/28/2021Credit Suisse GroupLower TargetOutperform$102.00 ➝ $100.00
10/28/2021Piper SandlerBoost TargetOverweight$119.00 ➝ $121.00
9/14/2021Leerink PartnersReiterated RatingBuy
9/9/2021Stifel NicolausUpgradeHold ➝ Buy$86.00 ➝ $96.00
9/7/2021Royal Bank Of CanadaReiterated RatingHold$88.00
9/7/2021WedbushReiterated RatingBuy$152.00
8/30/2021WedbushBoost TargetOutperform$141.00 ➝ $152.00
7/29/2021WedbushReiterated RatingBuy$141.00
7/29/2021Jefferies Financial GroupInitiated CoverageBuy$112.00
7/29/2021Royal Bank Of CanadaBoost TargetSector Perform$87.00 ➝ $88.00
7/29/2021Piper SandlerBoost TargetOverweight$112.00 ➝ $119.00
7/16/2021WedbushReiterated RatingBuy$141.00
7/11/2021Leerink PartnersInitiated CoverageBuy$83.62
7/2/2021Leerink PartnersReiterated RatingBuy
6/29/2021WedbushReiterated RatingBuy$141.00
4/28/2021WedbushReiterated RatingBuy$139.00
4/26/2021Credit Suisse GroupInitiated CoverageOutperform$102.00
4/19/2021Morgan StanleyLower TargetEqual Weight$85.00 ➝ $82.00
3/23/2021WedbushReiterated RatingOutperform$139.00
3/1/2021Evercore ISIUpgradeIn-Line ➝ Outperform$90.00 ➝ $100.00
3/1/2021Robert W. BairdReiterated RatingBuy
1/11/2021Robert W. BairdBoost TargetPositive ➝ Outperform$100.00 ➝ $110.00
(Data available from 12/4/2020 forward)

News Sentiment Rating

1.31 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/8/2025
  • 43 very positive mentions
  • 12 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
6/7/2025
  • 23 very positive mentions
  • 12 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
7/7/2025
  • 32 very positive mentions
  • 19 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
8/6/2025
  • 57 very positive mentions
  • 18 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
9/5/2025
  • 38 very positive mentions
  • 21 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
10/5/2025
  • 39 very positive mentions
  • 42 positive mentions
  • 12 negative mentions
  • 1 very negative mentions
Mentions as of
11/4/2025
  • 57 very positive mentions
  • 12 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
12/4/2025

Current Sentiment

  • 57 very positive mentions
  • 12 positive mentions
  • 1 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

BioMarin Pharmaceutical logo
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc. The company was incorporated in 1996 and is headquartered in San Rafael, California.
Read More

Today's Range

Now: $53.82
Low: $53.64
High: $54.66

50 Day Range

MA: $53.87
Low: $51.46
High: $56.29

52 Week Range

Now: $53.82
Low: $50.76
High: $73.51

Volume

1,886,729 shs

Average Volume

2,979,038 shs

Market Capitalization

$10.34 billion

P/E Ratio

20.23

Dividend Yield

N/A

Beta

0.3

Frequently Asked Questions

What sell-side analysts currently cover shares of BioMarin Pharmaceutical?

The following equities research analysts have issued research reports on BioMarin Pharmaceutical in the last twelve months: Bank of America Corporation, Barclays PLC, Cantor Fitzgerald, Citigroup Inc., Guggenheim, HC Wainwright, JPMorgan Chase & Co., Leerink Partners, Leerink Partnrs, Morgan Stanley, Oppenheimer Holdings, Inc., Piper Sandler, Raymond James Financial, Inc., Royal Bank Of Canada, Sanford C. Bernstein, Scotiabank, Stifel Nicolaus, The Goldman Sachs Group, Inc., Truist Financial Corporation, Tudor Pickering, UBS Group AG, Wall Street Zen, Wedbush, Weiss Ratings, Wells Fargo & Company, Wolfe Research, and Zacks Research.
View the latest analyst ratings for BMRN.

What is the current price target for BioMarin Pharmaceutical?

0 Wall Street analysts have set twelve-month price targets for BioMarin Pharmaceutical in the last year. Their average twelve-month price target is $88.61, suggesting a possible upside of 64.6%. Piper Sandler has the highest price target set, predicting BMRN will reach $126.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $55.00 for BioMarin Pharmaceutical in the next year.
View the latest price targets for BMRN.

What is the current consensus analyst rating for BioMarin Pharmaceutical?

BioMarin Pharmaceutical currently has 1 sell rating, 8 hold ratings and 16 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for BMRN.

What other companies compete with BioMarin Pharmaceutical?

Other companies that are similar to BioMarin Pharmaceutical include Biogen, United Therapeutics, Incyte, Exact Sciences and Neurocrine Biosciences. Learn More about companies similar to BioMarin Pharmaceutical.

How do I contact BioMarin Pharmaceutical's investor relations team?

BioMarin Pharmaceutical's physical mailing address is 770 Lindaro Street, San Rafael CA, 94901. The biotechnology company's listed phone number is (415) 506-6700 and its investor relations email address is [email protected]. The official website for BioMarin Pharmaceutical is www.bmrn.com. Learn More about contacing BioMarin Pharmaceutical investor relations.